Key clinical point: Treatment with radiation therapy is safe and effective for men with prostate cancer and underlying inflammatory bowel disease, with no biochemical relapses during an early follow-up period.
Major finding: With a median time of 22 months to any GI toxicity, one IBD patient experienced a high-grade toxicity (grade 3 proctitis) and 3 patients reported hemorrhoidal flares as the most common low-grade toxicity.
Study details: The data come from an institutional database of 4245 men who underwent stereotactic body radiation therapy for prostate cancer, including 31 patients with underlying inflammatory bowel disease.
Disclosures: The study was supported in part by a grant from Accuray. The researchers had no other financial conflicts to disclose.
Source: Lischalk JW et al. Radiat Oncol. 2021 Jul 9 doi: 10.1186/s13014-021-01850-1 .